Blog
RSS FeedPosted by Michael Wonder on 11 Apr 2017
ICER posts draft scoping document on cognitive and mind-body interventions to treat chronic low back and neck pain
10 April 2017 - Report expected to review evidence on acupuncture, cognitive behavioural therapy, mindfulness, yoga, and tai chi; scoping document ...
Posted by Michael Wonder on 07 Apr 2017
Institute for Clinical and Economic Review's final report on treatments for rheumatoid arthritis finds evidence inadequate to distinguish overall benefits between newer agents and prices too high in relationship to the clinical value provided to patients
7 April 2017 - Final report and meeting summary reviews evidence on 11 targeted immune modulator drugs, including two currently under ...
Posted by Michael Wonder on 24 Mar 2017
ICER releases draft evidence report on crisaborole and dupilumab for atopic dermatitis
24 March 2017 - Public comment period open until 21 April. ...
Posted by Michael Wonder on 20 Mar 2017
Institute for Clinical and Economic Review to review certain non-pharmacologic interventions for chronic low back and neck pain in upcoming review
20 March 2017 - The Institute for Clinical and Economic Review will develop a report assessing the comparative clinical effectiveness ...
Posted by Michael Wonder on 18 Mar 2017
Institute for Clinical and Economic Review to produce "New Evidence Update" Including updated value-based price benchmarks for PCSK9 inhibitors to treat high cholesterol
17 March 2017 - Update will incorporate new data on outcomes for patients with atherosclerotic cardiovascular disease released during the ...
Posted by Michael Wonder on 16 Mar 2017
The Institute for Clinical and Economic Review appoints new members to each of its three independent evidence appraisal councils
15 March 2017 - New members bring expertise in broad range of perspectives, including bioethics, patient advocacy, policy, and clinical ...
Posted by Michael Wonder on 11 Mar 2017
Institute for Clinical and Economic Review releases revised report on targeted immune modulators for treatment of rheumatoid arthritis
10 March 2017 - Analyses of evidence on comparative effectiveness raise questions about current step therapy protocols, while net prices for ...
Posted by Michael Wonder on 06 Mar 2017
ICER's final report on disease-modifying therapies for multiple sclerosis finds most drugs are over-priced in relation to benefits for patients; highlights need for stakeholder collaboration to address system issues
6 March 2017 - Key policy recommendations call on manufacturers to cease price increases and payers to ease coverage restrictions and ...
Posted by Michael Wonder on 03 Mar 2017
Institute for Clinical and Economic Review publishes white paper on assessment and payment methods for gene therapies
3 March 2017 - Paper presents recommendations for improving evidence generation and assessment methods for gene therapies; also analyses the ...
Posted by Michael Wonder on 08 Feb 2017
Institute for Clinical and Economic Review to review treatments for ovarian cancer in upcoming report
8 February 2017 - Preliminary list of drugs to be reviewed includes rucaparib, niraparib and olaparib. ...
Posted by Michael Wonder on 01 Feb 2017
Institute for Clinical and Economic Review posts revised value assessment framework for public comment
1 February 2017 - Dr. Steven Pearson, ICER's President, will present proposed changes during 13 February webinar. ...
Posted by Michael Wonder on 06 Dec 2016
ICER posts draft scoping document on treatments for osteoporosis
5 December 2016 - Document will be open to public comment until 23 December 2016. ...
Posted by Michael Wonder on 02 Dec 2016
ICER's final report on targeted immunomodulators for plaque psoriasis offers guidance for policy and practice
2 December 2016 - Independent CEPAC votes on value and subsequent policy roundtable discussion suggest that drug prices after rebates ...
Posted by Michael Wonder on 13 Nov 2016
ICER to review drug treatments for osteoporosis in upcoming report
11 November 2016 - The ICER will develop a report assessing the comparative clinical effectiveness and value of emerging drug ...
Posted by Michael Wonder on 20 Oct 2016
Oncologists knock ICER's lung cancer cost-effectiveness review
20 October 2016 - Ahead of an ICER meeting to review evidence and vote on cost-effectiveness ratings for new medicines ...